The results of recent studies of the mechanism of leukotriene B,-induced hyperalgesia suggest a dependence on polymorphonuclear leukocytes (PMNLs).
Abstract
The results of recent studies of the mechanism of leukotriene B,-induced hyperalgesia suggest a dependence on polymorphonuclear leukocytes (PMNLs).
In this study, we addressed the contribution of PMNLs to hyperalgesia evoked by the peptide chemotactic factors N-formyl-methionyl-leucyl-phenylalanine (fMLP) and the anaphylatoxin fragment of the fifth component of the complement pathway (C,.) . Local injection of glycogen, which attracts but does not activate PMNLs, produced a marked shift to the left (toward lower concentrations)
in the concentration dependence curve of fMLP-induced hyperalgesia.
In addition, PMNL repletion by transfusion with syngeneic PMNLs reestablished fMLP-induced hyperalgesia in PMNL-depleted rats. Finally, supernatants from rat and human PMNLs, that had been stimulated with fMLP in vitro, produced hyperalgesia in PMNL-depleted rats. Preliminary characterization of the hyperalgesia-inducing activity released by stimulated PMNLs indicated that it is lipid in nature. The nonsteroidal anti-inflammatory indomethacin did not attenuate Csa and fMLP-induced hyperalgesia. Thus, the hyperalgesia produced by fMLP and Cla is similar to that produced by leukotriene B4 in that it is dependent on PMNLs and independent of the cycle-oxygenation of arachidonic acid. Taken together, these data suggest that structurally diverse PMNL-chemotactic factors produce hyperalgesia by a novel mechanism, involving PMNL-derived factors.
Leukotriene Bq (LTB,), a product of the Uipoxygenation of arachidonic acid, exhibits potent chemotactic and other activities for polymorphonuclear leukocytes (PMNLs) (Ford-Hutchinson et al., 1980; Goetzl and Pickett, 1980; Williams, 1983) . We recently reported that intradermal injection of LTB,, in rats, also stereospecifitally induces hyperalgesia, of a magnitude similar to that elicited by the same quantities of bradykinin (BK) and prostaglandin E2 (PGE,) (Levine et al., 1984) . LTB,-induced hyperalgesia was not attenuated by prior administration of indomethacin, indicating independence from the cycle-oxygenase pathway of arachidonic acid metabolism. Depletion of PMNLs, however, eliminated the hyperalgesia. Thus, the mechanism by which LTB, evokes hyperalgesia is distinguished Received January 29, 1985; Revised April 1, 1985; Accepted May 3, 1985 'This work was supported in part by Grants NS21647, AM32634, DE05369, HL31809, and All 9784 from the National Institutes of Health, and a grant from the Northern California Arthrrtrs Foundation.
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from that of PGE, and BK by its dependence on PMNLs and its independence from second mediators generated by the cyclooxygenation of arachidonic acid (Levine et al., 1984) .
In the present study, we report that two other potent chemoattractants for and activators of PMNLs, namely, N-formyl-methionyl-leucylphenylalanine (fMLP) (Showell et al., 1976) and the anaphylatoxin fragment of the fifth component of the complement pathway, Csa (Shin et al., 1968 ) also produce hyperalgesia in the rat. The hyperalgesia induced by fMLP and Csa resemble that evoked by LTB, in being independent of the cycle-oxygenation of arachidonic acid and susceptible to attenuation by PMNL depletion. Preliminary characterization of the hyperalgesia-inducing factor produced by stimulated PMNLs suggests that it is a lipid. These data further elucidate a novel mechanism by which humoral mediators of inflammation can elicit hyperalgesia.
Materials and Methods
The experiments were performed on 250. to 3.50gm male Sprague-Dawley rats (Bantin-Krngman, Fremont, CA). Hyperalgesia, or tenderness, was assessed as a decrease in the wrthdrawal threshold to a pressure that increases linearly wrth time, applied on the dorsum of a hindpaw (Randall and Selitto, 1957) . Withdrawal threshold was frrst measured In the absence of exogenous mediators.
Then, 10 ~1 of a test substance or its vehrcle were injected rntradermally Into the dorsum of one htndpaw. The skin was blackened over the injection site to identify the location for further testing. Withdrawal threshold was then remeasured 10, 20, 40, 60, and 120 min post-injection. The magnitude of the hyperalgesra induced by a test substance was calculated as the percentage decrease in pressure requrred to elicit withdrawal, relative to the base Irne. In the rat, the maximum decrease in mechanical nociceptive thresholds produced by test substances using the paw withdrawal test correlates well with the analgesic potency of intradermal injections of the same substance in humans (Evans, 1964; Ferriera, 1983) . The fMLP (Sigma Chemrcal Co., St. LOUIS, MO) was initially dissolved In 10 ~1 of dimethylsulfoxide to which, then, was added Hanks' balanced salt solution (HBSS) containing 0.1% ovalbumrn and 10 mM HEPES (pH 7.4). The final solution was sonicated for 30 mm to ensure complete solubilization of the fMLP. The Csa was prepared as previously described and purified partially by ion-exchange chromatography and gel filtration (Goetzl and Austen, 1974) ; the concentration of CBa in the stock solution was 0.4 pg/ml as assessed by specific radioimmunoassay (Upjohn Diagnostics, Kalamazoo, MI). The C,, was dissolved in the same vehicle used to dissolve the fMLP. lndomethacin (Sigma) was dissolved in 2% sodium bicarbonate and then titrated to pH 7.2 with phosphate buffer. lndomethacin (2 mg/kg) or an equivalent volume of vehicle was administered intraperitoneally 40 min prior to intradermal injectron of test substances. lndomethacin produced a small increase in paw wrthdrawal threshold. Therefore, the threshold determined 30 min after intraperitoneal injection of indomethacin or its vehicle was used as the base line for calculating the magnitude of the hyperalgesra produced by test substances. PMNLs in the peripheral circulation of rats were depleted by intravenous admrnistratron of hydroxyurea (E. R Squibb and Sons, Inc., Princeton, NJ) in doses of 200 mg/kg on day 1 and 100 mg/kg on days 2 and 3, prior to hyperalgesia testing (Johnson and Malik, 1980) . This protocol eliminated greater than 90% of PMNLs in the peripheral circulation as assessed by counts of Wright-stained smears of blood (Levine et al., 1984) . Significant depletion of other leukocytes was also observed.
Local accumulation of PMNLs in the skin of the paw was produced by lntradermal injection of 10 ~1 of 1% oyster glycogen (Baker Co., Phillipsburg, NJ) in normal saline. The glycogen was injected 3% hr before ititradermal injection of test substances into the same site. This procedure has been shown histologically to produce a leukocytic infiltrate in rat skin that is-at 3% hr-almost completely accounted for by Influx of PMNLs (Hurley, 1972; Wahba et al., 1984) . The paw withdrawal threshold measured 3% hr after glycogen Injection was used as the base line threshold for calculating hyperalgesic effects In response to subsequent lntradermal injections of test substances.
PMNLs for transfusion Into hydroxyurea-treated rats and for in vitro PMNL sttmulation experiments were obtained from peritoneal fluid of syngeneic rats 3% hr after intraperitoneal injection of 1% glycogen (15 ml). The glycogentreated rats were anesthetized with ether, and 15 ml of ice-cold Ca"-and Mg'+-free HBSS were injected into the peritoneal cavity. The rats then were sacrlflced with an overdose of ether. Their abdomens were gently massaged, and the peritoneal fluld was removed through a midline incision in the linea alba and pooled for each group of rats. One milliliter of citrate buffer (44 gm of sodium citrate and 16 gm of cltnc acid/liter) was added to each 15ml portion of pooled peritoneal fluid. PMNLs were recovered from the peritoneal fluld by centrifugation for 5 min at 600 x g. The PMNLs were then washed twice and resuspended in HBSS. The purity of the PMNLs, as assessed by Wright-stained smears, was greater than 95%. For PMNL repletion experiments, approximately lo6 PMNLs were resuspended In 0.25 ml of HESS containing 0.3% rat albumin and injected into an indwelling carotid artery cannula IO min before injecting test substances.
To study the hyperalgesiainducing factor produced by PMNLs, cell-free supernatant was prepared by incubating suspensions of 10' PMNL/ml at 37°C for 15 min with 10e6 M fMLP (i.e., stimulated) and vehicle alone (i.e., unstimulated) for the control. After centrifugation of the suspensions, the supernatants were collected and further fractionated or stored at -70°C for up to 4 days, until used for hyperalgesia testing. To determine whether the hyperalgesiainducing factor was also produced by human PMNLs, mixed leukocytes were obtained from citrate-anticoagulated blood of healthy human volunteers after dextran sedimentation of erythrocytes, as described (Goetzl and Austen, 1974) . PMNLs of greater than 95% purity were isolated by centrifugation of the mixed leukocytes on Ficoll-Hypaque (Boyum, 1968) . Purified human PMNLs were suspended at a concentration of approximately lo7 cells/ml in HBSS containing 0.1% ovalbumln and 10 mM HEPES (pH 7.4). Stimulated and control cell-free supernatants were prepared by the same procedure and suspended in the same vehicle used for rat PMNLs.
To obtain lipid and peptide-enriched fractions of the stimulated supernatants, two distinct methods of extraction were used. Peptides and other polar molecules were extracted from a 200.~1 aliquot of supernatant. The aliquot was acldlfied to pH 3 with 0.4 N HCI and then 800 &I of acetone were added. After refrigeration for 12 hr at 4"C, the aliquot was centrifuged at 100 x g for 5 min at 4O"C, and the acetone supernatant was evaporated to dryness under nitrogen, followed by resuspension of the peptides in vehicle (Chang and Leeman, 1970) . The supernatants from lo6 stimulated PMNLs were divided Into four equal allquots and Injected into four rats.
The lipid fraction was obtained by acidifying a 900.PI aliquot of supernatant to pH 4 with 0.4 N HCI, to which was added an equal volume of isopropanol, followed by extraction with 4 vol of ether. The ether layer was removed, evaporated to 5 to 10 ~1, and resuspended in MeOH for storage at -70°C under a nitrogen atmosphere (Matthay et al., 1984) . Prior to use, the fraction was evaporated to dryness and resuspended in vehicle. Preliminary resolution of hyperalgeslc lipid factors in supernatants from fMLP-stimulated and unstimulated PMNLs was performed by high pressure liquid chromatography (HPLC). The times of HPLC elution of synthetic prostaglandins, prostacyclins, thromboxanes, PAFacether, and the 8(R)all trans LTB, product of 15-lipoxygenation of arachidonic acid were determined in the same solvent system, to assess any relationship to the active lipid factors from stimulated PMNLs.
Time courses of the effect of different factors (see Fig. 1 (Fig. 1) . The hyperalgesia produced by intradermal injection of fMLP was detectable at a minimum dose of 0.044 ng (Fig. 2) , and at 0.44 ng of fMLP or 0.4 ng of CBa it produced hyperalgesia similar in magnitude and duration to that elicited by 20 ng of LTB, (Levine et al., 1984 PMNL dependence of hyperalgesia. Hydroxyurea-induced depletion of circulating PMNLs, which had no effect acutely on either the health of the rats or on paw withdrawal threshold, prevented the hyperalgesia elicited by both fMLP (4.4 ng) and Csa (0.4 ng) (Fig.  4) lower dose (0.00044 ng) was, in addition, significantly higher than the peak (25 + 3%) produced by the higher amount (4.4 ng) in rats that were not treated with glycogen (p < 0.01). PMNL supernatant-induced hyperalgesia. The supernatant of 1 O7 addition, the supernatant elicited some local soft tissue swelling. fMLP-stimulated rat PMNLs produced significant hyperalgesia in
The supernatant of unstimulated rat PMNLs (Fig. 5) did not produce PMNL-depleted rats (p < 0.05) (Fig. 5 ) that was similar in magnitude hyperalgesia. A significant level of hyperalgesia also was produced to that produced by 0.44 ng of fMLP in normal rats (Fig. 2) . In by the supernatant of 1 O7 fMLP-stimulated human PMNLs (30 f 4.5; n = 8; p < 0.025). lndomethacin did not significantly antagonize the hyperalgesia induced by supernatants of stimulated rat PMNLs (Fig.  5) . Finally, when the stimulated PMNL supernatant was extracted by two separate techniques designed to yield peptides and lipids, significant (p < 0.01) biological activity was demonstrated only in the lipid fraction (Fig. 5) . In preliminary experiments, the active factor in the lipid extract was further characterized by HPLC. The active HPLC fraction produced a peak hyperalgesic effect in PMNL-depleted rats (22 f 2.1, n = 8) significantly greater than that produced by control supernatant from unstimulated PMNLs (9 +_ 1.8, n = 8; p < 0.01). In addition, the HPLC fractions that coeluted with prostaglandins, prostacyclins, thromboxanes, and PAFacether did not produce significant hyperalgesia (maximum effect, 12 + 2.8, n = 8) with respect to supernatant from unstimulated PMNLs (p = not significant). The active factor coeluted with 8(R)all trans LTB, but was not further characterized structurally.
Discussion
Two potent chemoattractants for and activators of PMNLs, Csa and fMLP, not previously studied for their ability to affect sensory systems, both produced hyperalgesia, at low doses. The hyperalgesia produced was similar in time course to that recently reported for the hyperalgesia induced by a third PMNL-chemotactic factor, LTB, (Levine et al., 1984) . Since subnanogram doses of fMLP and Csa induce a significant decrease in nociceptive thresholds, they are more potent, on a molar basis, than other well characterized hyperalgesic compounds including BK and PGEa (Horton, 1963; Crunkhorn and Willis, 1971) .
Involvement of PMNLs in the hyperalgesia elicited by LTB,, fMLP, and C& is suggested by the ability of prior hydroxyurea treatment of rats, which depletes PMNLs (Wahba et al., 1984) to attenuate the hyperalgesra elicited by these compounds but not the hyperalgesia elicited by BK and PGE, (Levine et al., 1984) . Although hydroxyurea also depletes other circulating leukocytes and produces effects on non-hematopoietic cells (Calabresi and Parks, 1980 ) a specific contribution of PMNLs could be discerned from the transfusion studies in rats depleted of endogenous PMNLs. Transfusion of PMNLs (>95% pure) re-established the fMLP-induced hyperalgesia. Although it is possible that small numbers of non-PMNLs in the. transfusions could account for the reconstitution of the hyperalgesic response, it is most likely due to reintroduction of PMNLs since the majority of "non-PMNLs" observed on Wright-stained smears of transfused cells were, in fact, cytoplasm without nuclei, and since fMLP, Cs,, and glycogen are potent PMNL-chemotactic and -activating factors that are preferentially active for PMNLs.
Although glycogen, a potent leukocyte chemoattractant, which in the time interval following injection employed in this study selectively attracts PMNLs, did not produce significant hyperalgesia, it produced a large shift in the dose dependency relationship for fMLPinduced hyperalgesia. When fMLP was administered into the same intradermal site 3% hr after glycogen, a significantly larger hyperalgesic effect was produced by one-thousandth of the dose previously required to elicit a maximal response. These findings provide independent confirmation of the contribution of PMNLs to the hyperalgesia elicited by fMLP and other PMNL chemoattractants. In addition, these findings suggest that the hyperalgesia elicited by chemotactic factors requires both attraction and activation of PMNLs.
The PMNL is the principal effector cell in the inflammatory reaction, accumulating at sites of inflammation to destroy antigenic material. Chemoattractants, such as LTB,, fMLP, and C& initiate a series of coordinated events in PMNLs including chemotaxis, secretion of lysozomal contents, and generation of superoxide anions (Snyderman and Pike, 1984) . Although it is possible to elicit hyperalgesia in the absence of blood-borne elements (Lynn, 1977 ) the accumulation of PMNLs at sites of inflammation is commonly associated with marked hyperalgesia (e.g., gout) or pruritis (e.g. psoriasis), an allied pain sensation. Unfortunately, the regulation of PMNL function is complex and involves the release of a number of peptide and lipid factors which are potential candidates as mediators of hyperalgesia. There is little information, however, to suggest which of these factors are responsible for eliciting hyperalgesia, the characteristic sensory abnormality associated with inflammation.
The chemical nature of the substance(s) released from PMNLs, which elicit(s) hyperalgesia, was studied with supernatants from PMNLs stimulated, in vitro, with fMLP. The supernatants of stimulated PMNLs produced hyperalgesia in PMNL-depleted rats. The hyperalgesic factor in these supernatants was found in its lipid fraction. Preliminary characterization of the active factor, by HPLC, has also demonstrated that it does not co-migrate on HPLC with prostaglandins, prostacyclins, thromboxanes, or PAFacether. That it does co-elute with 8(R)all trans LTB4 is important since it has recently been suggested that products of the 15.lipoxygenase pathway of arachidonic acid are formed by activated PMNLs, other leukocytes and epithelial cells (Jubiz et al., 1981; Maas et al., 1982; Hunter et al., 1985) .
As previously reported for LTB, (Levine et al., 1984) indomethacin failed to block Cs,-and fMLP-induced hyperalgesia. Thus, the mechanism by which these three chemotactic factors produce hyperalgesia is distinguished from the mechanism of the hyperalgesia elicrted by BK and products of the cycle-oxygenation of arachidonic acrd such as E-type prostaglandins (Levine et al., 1984) .
In conclusion, the PMNL-chemotactic factors fMLP, Csa, and LTB, (Soter et al., 1983; Levine et al., 1984) all can produce hyperalgesia, the characteristic sensory abnormality associated with inflammation. Since one or more of these chemotactic factors are commonly present in inflammatory lesions, it is probable that this class of compounds could account for a large part of the hyperalgesia that develops in acute inflammation. The independence of the hyperalgesia elicited by these three substances from the cycle-oxygenation of arachidonic acid and its dependence on PMNLs suggest that this type of hyperalgesia is mediated by a novel biochemical pathway. Preliminary characterization of the hyperalgesia-producing factor secreted by activated PMNLs, in response to these stimuli, suggests that it is a lipid. Pharmacological agents that block steps in this pathway may constitute a novel class of analgesic compounds.
Note added in proof. We have tested the effect of intradermal injection of the naturally occurring 15-lipoxygenase pathway product of PMNLs, 8(R)all trans LTB4, and of 8(S)all trans LTB,, a stereoisomer, on the pressure nociceptive threshold. The 8(R)all trans LTB, isomer (100 ng) produced significant hyperalgesia when compared to the same volume of vehicle (-20 f 2.3%, n = 10 versus -5.1 f 2.3%, n = 20, p < 0.005 by Student's t test with Bonferroni's correction for multiple comparisons). In contrast, 8(S)all trans LTB, (100 ng) produced significant hypoalgesia (+9.0 f 3.5%, n = 20 versus -5.1 + 2.3%, n = 20, p < 0.005). These findings suggest that 8(R)all trans LTB.+ could be a hyperalgesic substance released by PMNLs when they are stimulated with chemotactic factors. The findings that only the 8(R)all trans isomer produced hyperalgesia whereas the 8(S) isomer produced significant hypoalgesia suggests that this effect is receptor mediated and that the 8(S) isomer may be an effective antagonist at this receptor site.
